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Abstract
Objective: We have previously reported high ten-week mortality from cryptococcal meningitis in Malawian adults following
treatment-induction with 800mg oral fluconazole (57% [33/58]). National guidelines in Malawi and other African countries
now advocate an increased induction dose of 1200mg. We assessed whether this has improved outcomes.
Design: This was a prospective observational study of HIV-infected adults with cryptococcal meningitis confirmed by
diagnostic lumbar puncture. Treatment was with fluconazole 1200mg/day for two weeks then 400mg/day for 8 weeks.
Mortality within the first 10 weeks was the study end-point, and current results were compared with data from our prior
patient cohort who started on fluconazole 800mg/day.
Results: 47 participants received fluconazole monotherapy. Despite a treatment-induction dose of 1200mg, ten-week
mortality remained 55% (26/47). This was no better than our previous study (Hazard Ratio [HR] of death on 1200mg vs.
800mg fluconazole: 1.29 (95% CI: 0.77–2.16, p = 0.332)). There was some evidence for improved survival in patients who had
repeat lumbar punctures during early therapy to lower intracranial pressure (HR: 0.27 [95% CI: 0.07–1.03, p = 0.055]).
Conclusion: There remains an urgent need to identify more effective, affordable and deliverable regimens for cryptococcal
meningitis.
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Introduction
Cryptococcal meningitis is the commonest cause of meningitis
in adults in sub Saharan African (SSA) countries with high HIV
seroprevalence [1]. The global incidence of cryptococcal menin-
gitis was estimated at 957,900 cases/year in 2009 and 75% of
cases occur in SSA [2]. In Blantyre, Malawi, C. neoformans was
responsible for 70% of adult CSF-culture positive meningitis
presenting to a tertiary referral hospital from 2000 until 2012 [3].
This burden of cryptococcal meningitis has not changed despite a
highly successful national programme of antiretroviral therapy
(ART) roll-out since 2004 [3].
Current gold standard induction therapy is two weeks of
amphotericin B and flucytosine [4,5]; however these drugs remain
largely unavailable in SSA including Malawi [6]. Amphotericin B
is not only expensive, but difficult to administer and associated
with toxicities which are challenging to monitor in resource-poor
settings. Consequently, high-dose oral fluconazole is widely used in
SSA, but has significantly weaker early fungicidal activity than the
gold standard regimen [4,7].
We have previously reported extremely poor outcomes from
cryptococcal meningitis in Blantyre, when treated with 800mg
daily oral fluconazole as induction therapy [8]. In 2011 the
Malawian national treatment guidelines regarding the manage-
ment of cryptococcal meningitis changed, increasing the initial
dose of fluconazole at treatment induction from 800mg to 1200mg
daily [9]. Many African health services elected to make this change
following a study that demonstrated better early fungicidal activity
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using 1200mg fluconazole than with 800mg [10]. We present a
pragmatic, prospective observational study of clinical outcomes
from cryptococcal meningitis using this dose, which is the current
standard of care for many African countries.
Methods
Queen Elizabeth Central Hospital (QECH) Blantyre is the
largest government hospital in Malawi and admits approximately
10,000 adult patients per year. All patients with clinical features of
meningitis undergo diagnostic lumbar puncture (LP). Inclusion
criteria were unchanged from the previous study [8].
Consecutive adult patients (age $16) with a first presentation of
cryptococcal meningitis were recruited between September 2012
and May 2013. The diagnosis was confirmed by positive India-Ink
microscopy of CSF or culture-confirmed C. neoformans from CSF.
Cryptococcal antigen testing (CrAg), quantitative cryptococcal
cultures and fluconazole resistance testing were unavailable.
Subjects’ clinical history, including HIV diagnosis and ART
history were recorded. Patients without a recent HIV test were
confidentially counselled and tested. Presence of focal neurological
deficit, Glasgow Coma Score (GCS) and modified Rankin score
(mRS) were recorded. mRS is a 6 point disability scale (0 = No
symptoms, 1= No significant disability, 2 = Minor disability, 3 =
Moderate disability, 4 = Moderate-severe disability, 5 = Severe
disability/bed-ridden). Patients were reviewed on admission to the
study, on discharge home, at four weeks and ten weeks from
diagnosis.
Patients were treated according to national guidelines with
1200mg fluconazole per day for two weeks at induction followed
by 400mg/day for a further 8 weeks, then lifelong secondary
prophylaxis at 200mg/day [9]. A small donated supply of
Amphotericin B was sporadically available for readmitted patients
with evidence of fluconazole failure and patients swapped to this
agent were withdrawn from the study. Patients not already
receiving ART were initiated 4 weeks after diagnosis. Although
national guidelines recommend daily LPs to serially reduce
intracranial pressure (ICP) during early therapy, this was
impossible due to staffing limitations and a lack of CSF
manometry equipment. Routine practice at QECH was to
undertake therapeutic LP in the event of symptoms suggesting
raised ICP (e.g. severe headache).
The study endpoint was mortality at 10 weeks from diagnosis.
Statistical analysis was undertaken using ‘‘R’’ (version 2.15.2).
Clinical parameters of study participants were compared with
those from our previous study [6] by a two sample Wilcoxon test
for continuous variables or a x2-test for categorical variables. The
study endpoint, and the relationships between prior ART or
repeat LPs and mortality were assessed by survival analysis using
Hazard Ratios (HRs) and Kaplan-Meier plots. The binomial exact
test was used to calculate confidence intervals (CI) around death
rates.
The study was prospectively approved by the University of
Malawi College of Medicine Research Ethics Committee
(COMREC no: P04/10/926). Informed written consent was
obtained from patients to enrol in the study. Informed written
consent was obtained from guardians if patients lacked mental
capacity, due to advanced cryptococcal disease, to provide valid
consent. The consent procedure and forms were reviewed and
approved by COMREC, including the guardian consenting
procedure. Two copies of the consent forms were signed per
patient; one was retained by the patient and another by the study
team.
Results
58 patients were screened for enrolment, 3 patients were
excluded because C. neoformans was isolated from blood only.
Five patients were lost to follow up and therefore not included in
the analysis. 3 patients were withdrawn because they were
switched to Amphotericin B therapy by their physician; 2 of
whom survived. Data from the remaining 47 patients is presented
here; 46 were CSF culture-positive for C. neoformans and one
patient was culture negative but India-Ink microscopy positive.
The median age was 35 years (Inter-quartile range [IQR]: 32–
40 years) and 51% (24/47) were male. All patients presented with
headache, the median duration at presentation was 7 days (IQR:
7–17 days). 24% (11/46) had a GCS,14/15. mRS scores showed
24/50 (51%) subjects had moderate to severe disability (grade 3–
5).
All patients were HIV infected with a median CD4 count of 36
cells/ml (IQR: 17–62 cells/ml). At baseline, 45% (21/47) were
taking ART for a median duration of 63 days (IQR: 21–551 days).
A further 17% (8/47) commenced ART during the course of the
study and 6% (3/47) had previously commenced ART but
defaulted treatment.
Mortality at 10 weeks was 55% (26/47). The median time to
death was 16 days (IQR: 7–49 days). In the previous cohort,
mortality at 10 weeks amongst patients who received fluconazole
800mg/day was 57% (33/58) and median time to death was 19
days (IQR: 6–61 days). Figure 1 shows Kaplan-Meier survival
plots for patients initiated on fluconazole 800mg (1A) and
fluconazole 1200mg (1B); there is no difference in survival
between the two induction doses. The HR for death on 1200mg
vs. 800mg was 1.29 (95% CI: 0.77–2.16, p = 0.332).
The only significant clinical differences between patients in this
study and the previous cohort pertained to ART; a higher
proportion of patients in the current study were taking ART at
enrolment and the duration of prior ART was longer (see
Table 1). In the current study, there was some evidence of
improved survival in patients on ART prior to enrolment (HR for
death in those who presented on ART vs. those not on ART: 0.48
[95% CI: 0.21–1.07, p = 0.071]). Combining all 105 patients
Figure 1. Kaplan-Meier Survival plot of patients on flucona-
zole. A: 800mg induction dose. B: Kaplan-Meier Survival plot of patients
on fluconazole 1200mg induction dose.
doi:10.1371/journal.pone.0110285.g001
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across both studies, mortality was not significantly affected by prior
ART (HR for death: 0.84 [95% CI: 0.49–1.46, p = 0.550]). No
other evidence of difference in clinical severity at presentation
between the two cohorts was observed.
Repeat CSF drainage was performed on 11/23 (23%) patients
in the current study and 16/58 (28%) in the previous cohort with
symptoms suggestive of raised ICP. In the current study, there was
weak evidence towards survival in patients who had repeat LPs
(HR for death if LP repeated: 0.27 [95% CI: 0.07–1.03,
p = 0.055]). When data from both studies were combined, this
weak survival evidence persisted (HR for death: 0.52 [95% CI:
0.25–1.07, p = 0.077]).
This study was not designed as a prospective randomised
controlled comparison two doses of fluconazole. Instead, we
present prospective observational data revealing death from
fluconazole in 55% (95% CI: 40–70%) patients treated with
1,200mg fluconazole and 57% (95% CI: 43–70%) patients treated
with 800mg fluconazole. Both studies indicate that cryptococcal
meningitis therapy based on induction with oral fluconazole,
whether at 800 or 1200mg/day achieves unacceptably poor
outcomes.
Discussion
A Ugandan study of fluconazole demonstrated higher EFA in
CSF at a daily dose of 1200mg than 800mg without increased
toxicity [10], and it was hoped that this would translate into
improved clinical outcomes. However, a more recent pharmaco-
kinetic-pharmacodynamic (PK-PD) model of treatment with
1200mg fluconazole predicted that only 67% of patients on this
dose will obtain adequate CSF drug concentrations to achieve
fungal stasis [11]. In our study, 10-week mortality from
cryptococcal meningitis in Malawi has not improved following
an increase in the induction dose of fluconazole from 800mg to
1200mg. The highest mortality occurred in the initial two weeks,
suggesting that rapid fungal clearance is essential for a good
clinical outcome.
Expanded access to ART in Malawi [12] meant that more
patients had received ART before recruitment to the current
cohort than in our previous study of fluconazole 800mg/day [8].
This raises the possibility that Immune Reconstitution Inflamma-
tory Syndrome (IRIS) masked a benefit from the higher dose of
fluconazole, however in the current study, there was slightly higher
survival in patients on ART and in a combined analysis of both
studies the effect of prior ART was non-significant. Secondly IRIS
is unlikely as these patients were culture positive with CD4 counts
,50 cells/uL at presentation. Overall, these data do not support a
negative confounding effect from IRIS.
Despite improved ART provision, there remains a large
population with advanced HIV in Blantyre, and there is an
urgent need to protect them from cryptococcal meningitis.
General strategies include earlier HIV diagnosis and treatment.
A specific approach with increasing evidence of cost-effectiveness
is CrAg screening and treatment of asymptomatic antigenaemia in
the ART clinic [13,14,15].
Several studies have reported that serial LPs to lower ICP
during treatment of cryptococcal meningitis may improve
outcomes [16,17]. Although Malawian national guidelines suggest
performing daily LPs during early therapy [9], there is neither
adequate staffing nor the equipment for this to be possible.
Without CSF manometers we could only repeat LPs on patients
with symptoms of raised ICP. There was weak evidence of
improved survival in this group. Importantly the individuals
selected for additional procedures had the worst initial symptoms;
these data support the importance of therapeutic CSF drainage.
The benefit of serial LPs may be even greater if they are routinely
guided by CSF pressure measurement.
The current and previous study recruited patients with similar
characteristics in the same setting, however they have limitations;
the studies were undertaken sequentially, not as part of a
combined randomised controlled trial. Furthermore, there was
some loss to follow up and it was different to monitor adherence to
therapy. Serial CD4-counts and HIV-viral loads were unavailable
preventing a formal diagnosis of IRIS. Nevertheless, the studies
provide important information on the treatment of cryptococcal
meningitis from an authentic high-burden setting.
Oral fluconazole is currently the only routinely available
therapy in much of SSA, but mortality rates are unacceptably
high. An increase in the recommended induction dose from
800mg to 1200mg daily has had no impact on clinical outcomes in
Malawi. There are on-going studies with even higher doses of
fluconazole, (ACTG study: http://clinicaltrials.gov/show/
NCT00885703) and of novel therapeutic strategies (‘‘Advancing
Table 1. Comparison of baseline variables between patients initiated on fluconazole 800mg and those initiated on fluconazole
1200mg.
Baseline variable
Patients initiated on Fluconazole 800mg OD
N=58 [8]
Patients initiated on Fluconazole 1200mg OD
N=47 p-valuea
Age in years, median (IQR) 32 (29–39) 35 (32–40) 0.130
Male sex, n (%) 33 (55) 24 (51) 0.824
Headache duration in days, median (IQR) 14 (5–30) 7 (7–17) 0.508
Cranial nerve palsy/localising signs, n (%)b 5 (10) 12 (21) 0.225
GCS ,14/15, n (%) 14 (25) 11 (24) 1
Modified Rankin Score.3/5, n (%) 24 (41) 23 (49) 0.564
HIV status known at recruitment, n (%) 35 (60) 35 (75) 0.187
CD4 count in cells/ml, median (IQR) 37 (11–58) 36 (17–62) 0.721
On ART at baseline, n (%) 13 (22) 21 (45) 0.027
Duration of prior ART, median (IQR)c 20 (5–67) 63 (21–511) 0.048
aContinuous variables analysed by Wilcoxon test, categorical variables analysed by x2-test test.
bIncludes blindness, cranial nerve palsies or focal weakness.
doi:10.1371/journal.pone.0110285.t001
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cryptococcal meningitis treatment in Africa’’ [ACTA] ISRCTN:
45035509). Whilst the outcome of these studies is awaited, there
remains an urgent need for expanded access to amphotericin B
and flucytosine across SSA.
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